New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients.

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in ...

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both ...

These functional modifications highlight monocyte ability to play a role in homeostasis and disease, even before their migration and differentiation in the tissues. Notably, monocyte precursors (in ...

Non-invasive biomarkers and scoring systems show strong capability in differentiating chronic liver disease from cirrhosis, ...

The European Commission (EC) has approved a Marketing Authorization (MA) for Tremfya (guselkumab) to treat adults with ...

The liver is famous for its remarkable ability to regenerate, but that healing power depends heavily on the actions of its resident immune cells. A ...

This study exploring the role of TRPV1 signaling in recruiting macrophages and promoting angiogenesis during tympanic membrane wound healing presents useful findings. However, the strength of evidence ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

A new study led by researchers at Hospital for Special Surgery (HSS) suggests that currently available therapies may help ...

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) ...